|
related topics |
{product, liability, claim} |
{stock, price, share} |
{stock, price, operating} |
{debt, indebtedness, cash} |
{tax, income, asset} |
{condition, economic, financial} |
|
We may not be able to settle all of our obligations to creditors.
We have no control over the development and commercialization of XERECEPT , which we have sold to Celtic Pharma, and as a result, we are dependent upon Celtic Pharma to obtain any value from this product candidate.
The approval of XERECEPT , the only investigational drug in which we retain any interest, by the FDA or other regulatory authorities is uncertain and will involve the commitment of substantial time and resources.
Even if XERECEPT is approved for commercialization, it may not be successfully commercialized or generate meaningful product revenues for us.
Celtic Pharma may not be successful in selling its rights to XERECEPT.
Risks Related to Our Financial Condition
The auction rate security we hold in our portfolio trades infrequently, its value has been estimated, and we may have to sell it at a loss
Risks Related to Our Common Stock
Our common stock stopped trading on the Nasdaq Capital Market on December 17, 2009, and we closed our stock transfer books as of this date, each of which will make it difficult for stockholders to trade their shares.
The market price of our common stock has been, and is likely to continue to be, highly volatile.
Full 10-K form ▸
|
|
related documents |
918112--8/31/2009--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/ |
1030206--2/2/2010--VASCULAR_SOLUTIONS_INC |
1030206--2/5/2008--VASCULAR_SOLUTIONS_INC |
1030206--2/3/2009--VASCULAR_SOLUTIONS_INC |
1091596--2/26/2007--CYTOMEDIX_INC |
59440--3/16/2007--VECTOR_GROUP_LTD |
882873--9/20/2007--UROLOGIX_INC |
1347022--2/12/2009--VeriChip_CORP |
10081--8/30/2006--BARR_PHARMACEUTICALS_INC |
882873--9/21/2009--UROLOGIX_INC |
1006195--6/8/2009--MATRIXX_INITIATIVES_INC |
1050007--11/29/2007--NUTRACEUTICAL_INTERNATIONAL_CORP |
882873--9/17/2010--UROLOGIX_INC |
874716--2/27/2008--IDEXX_LABORATORIES_INC_/DE |
810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC |
874710--9/28/2007--ALLIED_HEALTHCARE_PRODUCTS_INC |
811669--2/23/2007--UST_INC |
816284--2/18/2010--CELGENE_CORP_/DE/ |
882873--9/29/2008--UROLOGIX_INC |
874710--9/28/2006--ALLIED_HEALTHCARE_PRODUCTS_INC |
1104280--12/3/2010--SANGUI_BIOTECH_INTERNATIONAL_INC |
811669--2/24/2006--UST_INC |
1050007--11/20/2008--NUTRACEUTICAL_INTERNATIONAL_CORP |
1000736--3/2/2006--CAREMARK_RX_INC |
776008--3/14/2006--STAR_SCIENTIFIC_INC |
739944--3/11/2008--MEDTOX_SCIENTIFIC_INC |
862668--10/12/2010--ESCALON_MEDICAL_CORP |
893160--2/16/2007--VENTANA_MEDICAL_SYSTEMS_INC |
10456--2/19/2009--BAXTER_INTERNATIONAL_INC |
|